Among these, apixaban is notably preferred due to its strong safety record, particularly in high-risk populations and for long-term management of cancer-associated venous thrombosis (VTE).
Apixaban's proven safety in managing conditions like pulmonary embolism and deep vein thrombosis (DVT) stems from its ability to significantly reduce major bleeding events, as seen in both clinical trials and real-world data.
A meta-analysis conducted in Amsterdam, comparing various DOACs, found no significant difference in recurrence rates. However, apixaban's safety stood out, with a 40% reduction in major bleeding incidents, and data from the AMPLIFY trial showed a remarkable 69% reduction in major bleeding compared to other anticoagulants.
Real-world observational studies further emphasised apixaban's safety, particularly in reducing risks associated with major bleeding and intracranial hemorrhage, a critical factor in avoiding fatal complications of VTE.
Furthermore, apixaban's twice-daily dosing has proven to be safer for reducing major bleeding, even during the early phases of treatment for VTE. Across clinical trials and meta-analyses, apixaban consistently showed fewer bleeding events, which includes both major and clinically relevant non-major bleeding, when compared to its DOAC counterparts, such as rivaroxaban and dabigatran.
This favourable bleeding profile is significant, especially for patients who might otherwise discontinue anticoagulation therapy due to the inconvenience caused by frequent minor bleeding.
In terms of bleeding risks, apixaban offers key advantages, particularly in reducing intracranial bleeding by two-thirds. This reduction is crucial because intracranial hemorrhages are often fatal.
Moreover, apixaban demonstrates a unique ability to lower the risk of gastrointestinal (GI) bleeding, which remains a concern with other anticoagulants, including rivaroxaban and warfarin. Real-world studies have consistently reaffirmed apixaban's superior protection against GI bleeding, making it a safer option, particularly for patients at higher risk of this complication.
The benefits of apixaban extend beyond venous thrombosis to areas like atrial fibrillation and thromboprophylaxis for orthopaedic surgeries. In the ARISTOTLE trial, apixaban outperformed other treatments in stroke prevention and was associated with reduced major bleeding and overall mortality in patients with atrial fibrillation.
Similarly, for thromboprophylaxis following knee and hip replacement surgeries, apixaban lowered the occurrence of VTE without increasing bleeding risks - an advantage that distinguishes it from other DOACs in these settings.
When comparing anticoagulants like low-molecular-weight heparin (LMWH), warfarin, and DOACs, particularly in terms of bleeding risks, studies such as the Einstein Extension study have provided valuable insights.
For instance, apixaban 2.5mg twice daily showed no significant difference in clinically relevant bleeding compared to other doses, reaffirming the safety of its dosing regimen.
Meanwhile, dabigatran exhibited a five-fold increase in clinically relevant bleeding, highlighting the importance of managing drug dosing to balance efficacy and safety. Apixaban’s lower trough levels and higher peaks contribute to its reduced bleeding risk, making it a more manageable option for clinicians.
The role of randomised controlled trials (RCTs) versus real-world data is critical in assessing the performance of anticoagulants like apixaban. While RCTs are invaluable for establishing initial efficacy and safety, they often involve select populations and shorter follow-up periods.
In contrast, observational studies offer insights into how these drugs perform in broader, more diverse patient groups. For example, real-world data have been essential in understanding anticoagulant use in patients with chronic kidney disease (CKD) or obesity, populations often excluded from RCTs.
For patients with cancer-associated thrombosis, anticoagulation poses unique challenges due to higher recurrence rates and increased bleeding risks. DOACs, particularly apixaban, have demonstrated better safety profiles than LMWH in these patients.
In the Caravaggio study, which compared apixaban with LMWH, apixaban met the primary efficacy endpoint of non-inferiority while showing no significant difference in bleeding rates, reinforcing its status as a safer choice for patients at high risk, including those with GI or neurological cancers.
In summary, apixaban has emerged as the preferred anticoagulant due to its strong safety profile, particularly in reducing major bleeding risks and providing effective VTE management in high-risk populations like cancer patients. Both clinical trials and real-world evidence consistently highlight its advantages over other DOACs, solidifying its role in long-term anticoagulation therapy.
To watch a replay of the webinar, click here.
The webinar is accredited for one (1) ethics point. Once you have watched the replay, send an e-mail to john.woodford@newmedia.co.za and request to have your point allocated to your profile on the HPCSA database. Include the webinar name and your HPCSA number in your e-mail.
